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Abstract:  Simultaneous  or  sequential  exposure  to  multiple  chemicals  may  cause 
interactions in the pharmacokinetics (PK) and/or pharmacodynamics (PD) of the individual 
chemicals. Such interactions can cause modification of the internal or target dose/response 
of one chemical in the mixture by other chemical(s), resulting in a change in the toxicity 
from that predicted from the summation of the effects of the single chemicals using dose 
additivity. In such cases, conducting quantitative cumulative risk assessment for chemicals 
present as a mixture is difficult. The uncertainties that arise from PK interactions can be 
addressed  by  developing  physiologically  based  pharmacokinetic  (PBPK)  models  to 
describe the disposition of chemical mixtures. Further, PK models can be developed to 
describe mechanisms of action and tissue responses. In this article, PBPK/PD modeling 
efforts conducted to investigate chemical interactions at the PK and PD levels are reviewed 
to demonstrate the use of this predictive modeling framework in assessing health risks 
associated with exposures to complex chemical mixtures. 
Keywords:  pharmacokinetics;  pharmacodynamics;  mixture  interactions;  physiologically 
based pharmacokinetic/pharmacodynamic model 
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1. Introduction 
A challenge for estimating cumulative risks across multiple chemicals is determining whether the 
responses generated from exposures to multiple chemicals simultaneously are different from estimates 
based on the addition of individual responses. The hypothesis of dose additivity among chemicals in a 
mixture is typically evaluated through empiricism. If a greater response from the mixture is observed 
than  expected  from  the  sum  of  the  individual  chemicals,  the  mixture  response  is  described  as 
synergism  or  potentiation  (Figure  1).  If  a  lower  mixture  response  is  observed  than  expected,  the 
mixture response is described as antagonism or inhibition (Figure 1). To better distinguish additivity 
and non-additivity, many efforts have concentrated on improving the analytical capability to more 
accurately measure responses or on developing statistical methods to properly test the null hypothesis 
of  dose  additivity  [1].  Even  with  the  most  advanced  analytical  and  statistical  tools,  however, 
determining the cumulative risk from exposure to environmental chemicals is still a difficult challenge. 
Figure  1.  The  traditional  empirical  approach  for  examining  dose  additivity  between 
chemicals A and B. Additive: Same response from the mixture is observed from the sum of 
A and B. Synergism: A greater response from the mixture is observed than expected from 
the sum of  A and  B.  Inhibitory:  A lower response  from the  mixture is  observed than 
expected from the sum of A and B.  
 
In the absence of toxicity data on the mixture of concern, data on similar/related mixtures or data on 
individual chemicals in the mixture may be used for assessing cumulative risk from mixture exposures. 
Examples  of  methods  for  conducting  cumulative  risk  assessment  include  the  Hazard  Index  (HI) 
approach,  weight-of-evidence  modification  of  the  HI  approach,  the  toxicity  equivalency  factor 
approach, and the relative potency factor approach [2-4]. These methods, however, lack a mechanistic 
basis  and  thus  are  of  limited  utility  for  high-to-low  dose  or  animal-to-human  extrapolations.  For 
example, a study on a quaternary mixture of trihalomethanes (THMs) showed that the rat venous blood 
concentrations of each THM following the mixture exposure were significantly higher compared to 
blood concentrations observed after exposures to single chemicals [5]. This finding is consistent with 
the  occurrence  of  mutual  inhibition  of  hepatic  metabolism  from  THMs.  Without  considering  this Int. J. Environ. Res. Public Health 2011, 8                 
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kinetic information (i.e., competitive inhibition), one may not recognize that this non-additive result is 
unlikely to occur in humans since the threshold for significant metabolic inhibition is not reached at 
environmental concentrations. 
When  assessing  the  toxicity  and  the  resulting  risk  of  chemical  mixtures,  a  more  mechanistic 
approach should be taken to characterize the interactions among individual chemicals in a mixture. In 
this article, two types of interactions will be discussed: Pharmacokinetic (PK) and pharmacodynamic 
(PD)  interactions  [6].  Interactions  related  to  cell  signaling  networks  that  can  affect  a  common 
physiological process are also important when assessing cumulative risk, but are not the focus of this 
article. Simply put, PK depicts the process of chemicals being absorbed, distributed to, metabolized 
within, and eliminated (ADME) from various organs and tissues. The term „PK interaction‟ refers to 
the case in which one unit of applied dose to chemical “X” in the presence of other chemicals leads to 
more or  less  than one  unit of  target tissue  dose compared to  exposure  to  chemical “X” by itself  
(Figure 2). Most interactions studied to date are PK interactions. On the other hand, PD describes how 
chemicals bring about tissue responses. The term “PD interaction” refers to the case which one unit of 
target tissue dose brought about by chemical “X” in the presence of other chemicals leads to more or 
less than one unit of tissue response compared to response caused by chemical “X” by itself (Figure 3). 
With the proper identification of interactions occurring at various levels, a more integrated systems 
approach can then be applied to provide a better perspective on how both biology and biochemistry 
impact mixture toxicity and cumulative risk. 
Figure 2. The impact of pharmacokinetic (PK) interactions on target tissue dose. The term 
“PK interaction” refers to the case in which one unit of applied dose to chemical X in the 
presence of other chemicals leads to less (examples in Section 3.1) or more (examples in 
Section  3.2)  than  one  unit  of  target  tissue  dose  compared  to  exposure  to  chemical  X  
by itself.  
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Figure 3. The impact of pharmacodynamic (PD) interactions on tissue response. The term 
“PD interaction” refers to the case in which one unit of target tissue dose to chemical X in 
the presence of other chemicals leads to less (examples in Section 4.1) or more (examples 
in  Section  4.2)  than  one  unit  of  tissue  response  compared  to  exposure  to  chemical  X  
by itself. 
 
2. Computational Modeling of Chemical Interactions 
The  knowledge  on  PK  or  PD  interactions  can  be  integrated  in  a  quantitative  manner  with  a 
mechanistic model. A mechanistic model for chemical mixtures is composed of three major elements: 
(1)  The  interaction  among  individual  chemicals  in  the  mixture  at  the  level  of  PK  and  PD;  
(2)  Quantitative  descriptions  of  both  temporal  (i.e.,  concurrent  or  sequential  exposures)  and  dose 
relationships among individual chemicals; and (3) Each chemical‟s mode of action. Mode of action is 
the sequence of events by which the active form of the chemical (parent or metabolites) interacts with 
the  target  tissue  and  leads  to  responses.  A  commonly  used  computational  model  that  consists  
of all three elements described above is a physiologically based pharmacokinetic/pharmacodynamic 
(PBPK/PD) model. 
PBPK modeling involves the development of mass-balance differential equations to describe the 
ADME  processes  of  chemicals  as  a  function  of  their  physiochemical  (e.g.,  tissue:blood  partition 
coefficient),  biochemical  (e.g.,  metabolic  rate  constant),  and  physiological  (e.g.,  tissue  volume) 
characteristics. Typically, a PBPK model consists of a series of biologically relevant compartments, 
each receiving the chemical via the arterial blood and returning the free chemical via the venous blood. 
These compartments may represent a single tissue or a group of tissues with similar blood flow and 
solubility characteristics.  
PBPK  models  of  chemical  mixtures  involve  the  change  of  rates  of  ADME  for  one  or  more 
chemicals. The alteration of the absorption/excretion rate of a chemical as a result of the presence of 
other  chemicals  is  often  caused  by  interference  with  an  active  uptake/excretion  process  or  by 
modulation  of  critical  biological  determinants  of  uptake  (e.g.,  breathing  rate)  or  excretion  
(e.g., glomerular filtration). The distribution rate can change when multiple chemicals compete for 
binding to the same macromolecules (e.g., hemoglobin, albumin, metallothionein) or proteins. The Int. J. Environ. Res. Public Health 2011, 8                 
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enhancement of metabolic rate (induction) can occur in the case when specific isoenzymes are induced 
by prior exposures to certain chemicals, leading to an increase in the enzyme capacity to metabolize 
other chemicals. The reduction of metabolic rate (inhibition) is a result of two or more chemicals 
competing for biotransformation mediated by the same enzyme. With environmental chemicals, the 
most  common  single  mechanism  of  interaction  investigated  is  inhibition  or  induction  of  hepatic 
cytochrome P450 by mixtures of chemicals [7,8]. Metabolism plays an important role in the toxicity of 
many chemicals, either by the detoxification of a directly toxic compound or by the formation of a 
metabolite that is more reactive than the parent compound [9].  
Besides simulating the ADME processes, PBPK models also have the capability to simulate target 
tissue dose, which is the determinant of tissue reactions leading to toxicity [10]. Thus, a PBPK model 
can be connected to a PD model to simulate the time course of tissue response as a function of target 
tissue dose. The quantitative descriptions of PK and PD of individual chemicals in PBPK/PD models 
allows one to investigate the possibility and degree of interactions among chemicals in the PK and PD 
processes  at  different  exposure  scenarios.  This  modeling  approach  provides  a  means  to  evaluate 
mixture interactions and associated cumulative risk that are not readily available from observing the 
temporal  and  dose-response  relationship  of  co-existing  chemicals  (i.e.,  empiricism).  In  addition, 
modeling approach has the capability to answer questions for experiments that would be too costly and 
complex to perform.  
Another advantage of analyzing mixture interactions with a PBPK model is that mixture exposure 
may result in altering one biomarker while other biomarkers of the same chemical remain unchanged. 
For  example,  Tardif  and  Charest-Tardif  exposed  rats  for  4  h  to  1,1,1-trichloroethane  or  m-xylene  
alone  or  as  a  mixture  and  found  that  the  blood  concentration  of  1,1,1-trichloroethane  was  not  
affected  whereas  that  of  m-xylene  was  increased  [11].  They  also  found  that  the  excretion  of  
1,1,1-trichloro-ethane metabolites (trichloroethanol and trichloroacetic acid) during a period of 48 h 
following  the  onset  of  exposure  was  significantly  reduced  [11].  These  results  were  successfully 
simulated using a PBPK model with a description of competitive inhibition in the liver [7].  This 
example  highlights  the  importance  of  conducting  quantitative  analysis  of  PK  and  PD  interactions 
before  selecting  appropriate  biomarkers  to  study  mixture  interactions.  In  the  following  sections, 
examples will be provided to further illustrate mixture interactions at the PK and PD levels. In addition, 
these examples will demonstrate how computational models can be used to enhance our ability to 
evaluate cumulative risk following mixture exposures by incorporating the interaction mechanisms.  
3. Examples of Pharmacokinetic Interactions among Mixtures 
3.1. Decreased Tissue Dose in the Presence of Other Chemicals 
3.1.1. Trichloroethylene (TCE) in a Mixture 
TCE  is  a  common  organic  solvent  used  in  industry  worldwide;  it  is  also  a  widespread 
environmental chemical. In animal studies, TCE has shown to induce various toxicological effects in 
kidneys,  liver,  and  lungs  that  may  be  attributable  to  its  metabolites  [12].  Several  studies  were 
conducted  to  investigate  the  toxicological  interactions  between  TCE,  its  metabolites,  and  other 
chemicals including solvents, haloacetates, and ethanol [13]. In this section, two of these studies are Int. J. Environ. Res. Public Health 2011, 8                 
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presented on the suppressive effects on TCE metabolism due to co-exposure to other chemicals. The 
first study is on the mixture of TCE,  perchloroethylene (PERC) and 1,1,1-trichloroethane (methyl 
chloroform, MC) [14]; this mixture is listed on the U.S. Environmental Protection Agency (EPA) 
National Priorities List (NPL) among the most frequently detected ternary mixtures in air at the current 
and former hazardous waste sites [15]. As these three chemicals undergo concurrent P450-catalyzed 
oxidation in liver, potential PK interactions (and subsequent impact on toxicity) may occur [16,17]. To 
investigate the interaction, Dobrev and colleagues built three PBPK models, one for each chemical, 
that share an identical model structure [14]. Then, these three models were linked by implementing 
alternative inhibitory metabolism equations (competitive, uncompetitive, and non-competitive) in the 
liver  compartments.  Model  simulations  using  each  of  the  alternative  equations  were  compared  to 
chemical  concentrations  measured  in  the  gas  phase  of  the  closed-chamber  to  determine  which 
inhibition mechanism is most plausible. Dobrev and colleagues found that the competitive inhibition 
equation best described the pharmacokinetics of the ternary mixture: Co-exposure to PERC and MC 
result in a significant reduction of TCE metabolism at high exposure concentrations, but less so at low 
environmental exposure concentrations [14].  
The second TCE study investigated the basis for decrease in 1,1-dichloroethylene (DCE) toxicity 
when rats were co-exposed to TCE [18]. 1,1-DCE is a potent hepatotoxicant that exerts acute toxicity 
when its reactive metabolites are formed faster than they can be detoxified by glutathione (GSH) [19]. 
Since both 1,1-DCE and TCE are metabolized by CYP2E1 in the liver, Andersen and colleagues built a 
PBPK model for the binary mixture with each chemical as an inhibitor of the other‟s metabolism [18]. 
Similar to the study described above [14], multiple mechanisms of inhibitory interactions were examined 
by comparing model simulations with measured chemicals concentrations in gas chamber [18]. The best 
correspondence  between  predicted  and  observed  time  course  behaviors  was  obtained  when  the 
inhibition was assumed to be competitive. In addition, the PBPK model with the competitive inhibition 
equation was able to predict the decreased 1,1-DCE hepatotoxicity (serum aspartate transaminase as a 
surrogate) due to decreased metabolism when co-exposed to TCE [18]. It is important to note that a 
PBPK model has the capability to analyze co-exposure effects on metabolism and toxicity due to other 
PK  interactions.  For  example,  a  PBPK  model  that  describes  GSH  depletion  associated  with 
metabolism can be used to evaluate the alteration of 1,1-DCE hepatotoxicity as a result of co-exposure 
to vinyl chloride, since both chemicals deplete GSH due to a formation of reactive metabolites [20].  
3.1.2. Toluene in a Mixture 
Purcell and colleagues conducted a series of gas uptake studies with a binary mixture of toluene and 
benzene at different initial concentrations [21]. The temporal change in the gas chamber concentrations 
was  analyzed  with  a  rat  PBPK  model  that  has  a  metabolic  interaction  term  defined  in  the  liver 
compartment. Purcell and colleagues found that the non-competitive inhibitory equation provided the 
best simulation fit to all experimental data, suggesting that toluene was a better inhibitor of benzene 
metabolism  than  benzene  was  of  toluene  metabolism  [21].  Building  upon  this  work,  Tardif  and 
colleagues  assessed  the  metabolic  interactions  of  a  ternary  mixture  of  toluene,  m-xylene,  and 
ethylbenzene (TEX) with a rat PBPK model and gas uptake studies [22]. After determining that the 
competitive  metabolic  inhibition  was  the  most  plausible  mechanism  of  interaction  for  the  ternary Int. J. Environ. Res. Public Health 2011, 8                 
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mixture, the rat model was scaled to a human model. Based on the human model simulations and 
human volunteer studies, Tardif and colleagues found that the alveolar air concentrations and urinary 
metabolite concentrations of TEX were not significantly different between individual and combined 
exposures at atmospheric concentrations that were within the permissible concentrations [22].  
In later studies, Haddad and colleagues developed a PBPK mixture modeling framework that allows 
for adding or substituting chemicals to an existing mixture model by characterizing the new binary 
interactions  between  the  new  chemical  and  pre-existing  mixture  components  [23,24].  More 
specifically, Haddad and colleagues added a pre-established PBPK model for benzene (B) to the TEX 
mixture model [23]; and later added a pre-established PBPK model for dichloromethane (D) to their 
BTEX model [24]. The structure and parameter values of the existing models remain unchanged, 
except that the competitive inhibition of hepatic metabolism at the binary level was added to link an 
individual model to a mixture model. Both the BTEX and the DBTEX models were able to predict the 
time course of venous blood concentrations in rats following a 4-h inhalation exposure to various 
mixtures [23,24]. These studies demonstrated a “bottom-up” mixture modeling methodology that uses 
available data on binary chemical interactions to link existing PBPK models of single chemicals to 
predict their PK consequences in a complex mixture. When data on binary chemical interactions are 
not  available,  this  modeling  methodology  may  still  be  used  with  tools  such  as  quantitative  
structure-activity relationship (QSAR) to simulate chemical interactions in a mixture. For example, 
Price  and  Krishnan  recently  demonstrated  the  use  of  QSAR  to  estimate  partition  coefficients, 
maximum rates of metabolism (VMax), and Michaelis constants (Km) based on chemical structure for 
53 volatile organic compounds (VOCs) [25]. They then set the metabolic inhibition constant equal to 
Km in a mixture PBPK model to predict the inhalation pharmacokinetics of VOCs in various mixtures. 
This study demonstrated the use of QSAR in PBPK modeling to provide first-cut evaluations of the 
kinetics of mixtures of VOCs in rats [25].  
For a mixture that contains a large number of chemicals, such as gasoline, the bottom-up approach 
is not practical since it requires data on binary chemical interactions for all components in the mixture. 
Rather, a “top-down” (or lumping) approach can be used when it is not necessary to distinguish a 
specific chemical from the mixture (e.g., no relevant toxicity data), and when the properties of lumped 
chemicals  can  be  described  by  a  central  estimate  [26].  For  example,  Dennison  and  colleagues 
developed a mixture PBPK model that consists of five target chemicals (BTEX and n-hexane) and a 
lumped chemical group that represents all other chemicals in gasoline [26]. Similar to the studies 
described above, individual PBPK models were linked by describing the competitive inhibition of 
hepatic metabolism at the binary level. Using the PBPK model and the lumping approach, Dennison 
and colleagues were able to predict the pharmacokinetic behaviors of the five target chemicals in rats 
that were exposed to single chemicals and mixtures in closed-chamber studies [26]. 
 
3.2. Increased Tissue Dose in the Presence of Other Chemicals 
3.2.1. Carbon Tetrachloride (CCl4) and Methanol 
From animal studies, the main adverse effects associated with inhaled CCl4 exposure are central 
nervous system depression and liver/kidney damage, with liver being the most sensitive target [27]. Int. J. Environ. Res. Public Health 2011, 8                 
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Most  of  the  toxic  effects  of  CCl4  are  related  to  its  metabolism  by  cytochrome  P450  oxygenase, 
primarily  CYP2E1.  In  addition  to  metabolism,  Mehendale  suggested  that  CCl4-mediated 
hepatotoxicity  could  be  potentiated  by  any  mechanism  that  destructs  hepatocellular  regenerative 
capacity [28]. In this example, Evans and Simmons tested, using gas uptake studies and a mixture 
PBPK model, the hypothesis that the induction of CCl4 metabolism is the primary mechanism involved 
in potentiation of CCl4 hepatotoxicity in rats when they were pre-treated with methanol [29]. First, the 
maximum metabolic rates (Vmax) of CCl4 in the PBPK model was estimated by fitting the model 
predictions with the uptake of CCl4 observed in the gas uptake studies under two conditions: With and 
without  methanol  pretreatment  [29].  This  strategy  allowed  enzyme  induction  after  methanol 
pretreatment (assuming CYP2E1 is the only isozyme involved) to be modeled with increased Vmax 
value.  Their  modeling  results  did  show  that  Vmax  was  significantly  increased  when  rats  were  
pre-treated with methanol, indicating a potential PK interaction between the methanol and CCl4.  
Subsequently, Evans and Simmons examined the alteration in CCl4 hepatotoxicity by comparing the 
serum markers of alanine aminotransferase (ALT) and sorbitol dehydrogenase (SDH) in rats that were 
exposed  to  the  binary  mixture,  and  in  those  that  were  exposed  to  CCl4  alone  [29].  Since  overt 
hepatotoxicity was not observed with inhaled methanol alone [30], an increased ALT/ SDH level from 
the mixture exposure would suggest that potentiation of CCl4 hepatotoxicity are due to rats being 
exposed to the binary mixture. Evans and Simmons observed a dose-dependent increase in serum ALT 
and  SDH  levels  when  rats  were  exposed  to  both  methanol  and  CCl4  [29].  This  increase  was 
significantly higher when compared to ALT and SDH levels from CCl4-alone exposure. In addition, it 
was found that given the same mixture concentration, serum ALT and SDH levels were higher at 24 h 
post-exposure than at 48 h post-exposure [29]. This time difference (24 vs. 48 h) in ALT and SDH 
levels suggested that not only is there a PK interaction, but also a PD interaction between the methanol 
and  CCl4.  In  addition  to  metabolic  induction,  Evans  and  Simmons  proposed  that  Kupffer  cell 
activation might be involved in enhanced CCl4 hepatotoxicity with methanol co-exposure [29].  
3.2.2. Mirex, Phenobarbital, Chlordecone and Bromotrichloromethane (BrCCl3) 
In this example, using PBPK modeling and gas uptake studies, Thakore and colleagues examined 
the effect of dietary pretreatment with Mirex, Phenobarbital, and Chlordecone on the metabolism of 
BrCCl3 [31]. The change of metabolic rate constants in a BrCCl3 PBPK model was examined by fitting 
the model predictions with the decline in the chamber concentrations of BrCCl3, with and without 
pretreatment of other chemicals. Similar to the previous example of CCl4, this study also evaluated the 
increased BrCCl3 hepatotoxicity following pretreatment of other chemicals. It was found that the mild 
enhancement of BrCCl3 toxicity by Mirex and Phenobarbital correlated with an increase in metabolism; 
but  the  marked  potentiation  seen  after  chlordecone  pretreatment  could  not  be  attributed  to  the 
induction of BrCCl3 metabolism [31]. Additional experimental evidence indicated that this potentiation 
phenomenon is a result of chlordecone interfering with the initial tissue repair process that follows 
BrCCl3-induced  liver  injury  [28].  This  is  another  example  of  chemical  interactions  at  both  PK  
and PD levels.  
 Int. J. Environ. Res. Public Health 2011, 8                 
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4. Examples of Pharmacodynamic Interactions among Mixtures 
4.1. Decreased Tissue Response in the Presence of Other Chemicals 
The first example of PD interaction is a modeling exercise on identifying the interaction thresholds 
for  chlorpyrifos  and  parathion  mixture  [32].  Chlorpyrifos  and  parathion  both  belong  to  the 
organophosphates (OP) family; they are potent pesticides that inhibit acetylcholinesterase (AChE) of 
many agricultural and household pests. They are found together in the environment, and humans may 
be exposed to these pesticides through oral, dermal and inhalation routes. Potential adverse effects 
following exposures include neurological, developmental, cardiac, respiratory, hepatic, hematological, 
metabolic,  muscular,  and  pancreatic  effects,  among  which  neurological  effects  are  of  the  most  
concern [33]. The mechanism of neurotoxicity for chlorpyrifos and parathion is similar—the active 
metabolites of both pesticides inhibit AChE resulting in prolonged stimulation of the acetylcholine 
receptors on the postsynaptic cells, leading to the subsequent neurotoxic effects. The competition in 
inhibiting AChE by these active metabolites is an interaction at the PD level. 
Besides  having  a  similar  mechanism  in  AChE  inhibition,  chlorpyrifos  and  parathion  also  have 
similar  metabolic  pathways.  Chlorpyrifos  is  rapidly  desulfurated  by  CYP450  3A4  and  2D6  to 
chlorpyrifos-oxon [34,35]. Chlorpyrifos-oxon is 300 to 400 times more potent at inhibiting rat brain 
AChE than chlorpyrifos [36]. Parathion is desulfurated by P450 3A4, 3A5, 1A2, and 2D6 to paraoxon 
in liver [37,38]. Paraoxon is also a much more active inhibitor of AChE than its parent. Since the same 
isoenzymes P450 3A4 and 2D6 are involved in the metabolism of both chemicals to the oxon that 
inhibits  AChE,  El-Masri  and  colleagues  used  a  mixture  PBPK/PD  model  that  consists  of  four 
individual sub-models (chlorpyrifos, chlorpyrifos-oxon, parathion, paraoxon) to evaluate the PK and 
PD interactions between chlorpyrifos and parathion [32].  
El-Masri and colleagues described competitive inhibition in the two parent models, which were 
linked to their metabolite models in the liver compartments [32]. The predicted concentrations of the 
metabolites  in  blood  were  linked  to  a  PD  model  for  AChE  kinetics  where  the  competition  for 
cholinesterase occurs. Partition coefficients, metabolic, and biochemical parameters in the model were 
obtained from the literature. Binding constants for both chlorpyrifos-oxon and paraxon to AChE were 
optimized to fit inhibition data found in the literature. The calibrated model was then used to determine 
the presence of an interaction threshold for AChE inhibition between chlorpyrifos and parathion when 
administered orally. In this study, the interaction threshold was determined by comparing the area 
under  the  free  AChE  activity  curve  (AUC)  of  the  mixture  exposure  and  the  added  AUCs  of  the 
chlorpyrifos-oxon only exposure and the paraoxon only exposure. As expected, a decrease of tissue 
response (e.g., AChE inhibition) was exhibited at high oral dose exposure to the binary mixture, and 
the inhibition interaction became smaller as the dose reduced [32]. A similar PBPK/PD modeling 
approach was used by Timchalk and Poet to evaluate the binary mixture of chlorpyrifos and diazinon, 
which is another OP [39]. The mixture model described the metabolic interactions using inhibition 
kinetics,  and  described  B-esterase  metabolism  and  cholinesterase  inhibition  as  dose-additive.  The 
model was able to simulate, in rats, the time-course of both chemicals and their metabolites in blood, 
as well as cholinesterase inhibition in plasma, red blood cells, and brain, following oral exposures to 
the mixture [39]. Similar PK and PD interactions can also be found in mixture of pesticides from Int. J. Environ. Res. Public Health 2011, 8                 
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different  families.  Carbamates,  just  like  OP,  inhibit  AChE  and  are  metabolized  by  cytochrome  
P450-mediated monooxygenases. In this next example, the PK and PD interactions between carbaryl 
(a carbamate pesticide) and chlorpyrifos are discussed. Carbaryl and chlorpyrifos are both widely used 
pesticides for which individual PBPK models have been developed [40,41]. An important distinction 
between  these  two  pesticides  is  that  while  the  interaction  of  chlorpyrifos-oxon  with  AChE  is 
essentially irreversible, the interaction of carbaryl (which is the active AChE inhibitor) with AChE is 
rapidly reversible. To study the binary mixture of carbaryl and chlorpyrifos, the PBPK models for 
carbaryl  and  chlorpyrifos  were  linked  through  descriptions  of  competitive  inhibition  at  sites  of 
metabolism and at AChE [42]. The linked mixture model predicted a complex time course for AChE 
that reflects the combination of the rapid but reversible binding of carbaryl to AChE together with the 
slower, irreversible binding of chlorpyrifos-oxon to AChE.  
4.2. Increased Tissue Response in the Presence of Other Chemicals 
Potentiation  of  CCl4  hepatoxicity  is  used  again  to  discuss  the  role  of  PD  interactions  among 
chemicals.  To  explain  the  different  potentiated  CCl4  hepatotoxicity  when  co-exposed  to  Kepone, 
(chlordecone). Mehendale proposed a “two-stage model of toxicity” concept. In the first stage, cellular 
and/or tissue injury inflicted by toxic chemicals evokes  homeostatic mechanisms, such as cellular 
proliferation and tissue repair, to restore the original tissue structure [43]. With no additional toxic 
assaults, complete and prompt recovery is expected from the toxicant-induced injury. Blocking or 
pertubing the homeostatic mechanism with additional exposures, however, would lead to the second 
stage of toxicity where progression of extensive injury occurs. This concept could explain the marked 
amplification  of  CCl4  hepatotoxicity  and  lethality  following  pre-exposure  to  a  non-toxic  level  of 
Kepone [44,45] or other halomethanes [28,43].  
Lockard and colleagues exposed rats to 0.1 ml/kg CCl4 via a single intraperitoneal injection, and they 
observed limited hepatocellular necrosis accompanied by ballooned cells and steatosis [46,47]. Within  
6 h after exposure, liver tissues responded to the toxicity by stimulating hepatocellular regeneration and 
tissue repair [46,47]. The repair mechanism continued after the hepatocellular necrosis advanced to a 
more  progressive  phase  between  6  and  12  h  following  exposure.  In  addition  to  restoring  the 
hepatolobular structure by replacing dead cells, the newly generated cells also demonstrated resistance to 
the existed toxicity [48]. With these more resistant new cells, the regenerated liver was able to endure a 
greater assault in the progressive phase and fully recover later [43]. 
But,  if  animals  which  were  administered  the  same  dose  of  CCl4  were  pretreated  with  10 ppm 
Kepone, the liver injury observed in these animals became much higher compared to that observed in 
animals exposed to either chemical alone [46,47]. Kodavanti and colleagues suggested that the pre-
treatment  of  Kepone  suppressed  the  initial  hepatocellular  regeneration  and  thus  resulted  in  two 
consequences:  (1)  The  hepatolobular  structure  cannot  be  restored;  and  (2)  Liver  injury  at  the 
progressive phase accelerated in the absence of those newly divided, relatively resistant cells [49]. This 
hypothesis was further investigated in a Kepone/CCl4 mixture study with postnatal rats [50]. While rat 
pups at 2, 5, 20, and 35 days of age were completely resilient to Kepone potentiation of CCl4 toxicity, 
young rats by 60 days of age were as sensitive as adult rats. The hepatic microsomal cytochrome P450 
levels in the 35-, 45-, and 60-day-old rats exposed to Kepone were no different from each other, Int. J. Environ. Res. Public Health 2011, 8                 
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suggesting that PK interaction between Kepone and CCl4 cannot explain the observed discrepancy in 
potentiation of CCl4 toxicity between 35- and 60-day-old rats. It is more likely that the resiliency of 
younger rats to Kepone-potentiated CCl4 toxicity was related to the active hepatocellular regeneration 
during the early development stage [50].  
In a later study, El-Masri and colleagues constructed a PBPK/PD model that includes the following 
three effects of Kepone on CCl4 hepatotoxicity: (1) Inhibition of mitosis; (2) Reduction of the repair 
mechanism of hepatocellular injury; and (3) Suppression of phagocytosis [51]. The values for PD 
parameters  in  the  model  were  estimated  by  fitting  the  model  simulations  to  fractions  of  injured, 
pyknotic, and mitotic cells from rats exposed to CCl4 with and without Kepone [47]. The calibrated 
model was then used to predict the LD50 (the dose required to kill half of a tested population) for CCl4 
toxicity.  The  model  predictions  were  consistent  with  the  observed  mortality,  showing  a  ~60-fold 
amplification of CCl4 lethality in the presence of Kepone.  
In  another  study,  animals  were  co-exposed  to  CCl4  and  Phenobarbital  [48].  Enhanced  CCl4 
hepatotoxicity  was  observed,  but  no  significantly  increase  lethality  was  found  as  in  the  case  of 
Kepone/CCl4  co-exposure.  The  enhanced  hepatotoxicity  may  be  caused  by  the  induction  of 
cytochrome  P450  CYP2E1,  which  leads  to  increasing  CCl4  bioactivation.  But,  unlike  Kepone, 
Phenobarbital did not compromise the capability of hepatocellular regeneration. Thus, the potentiated 
CCl4  hepatotoxicity  was  able  to  be  reversed,  though  being  delayed,  by  stimulated  hepatocellular 
regeneration  and  tissue  repair  mechanism  [43].  Both  Kepone  and  Phenobarbital  potentiate  CCl4 
hepatotoxicity, but the ultimate outcome (lethality or reversible vs. irreversible toxicity) is determined 
by the interaction mechanisms.  
5. Applications in Assessing Human Health Risks 
Most studies reviewed in Sections 3 and 4 were conducted in animals. Only a few studies used 
computational models to examine the effects of PK interactions among chemicals in a mixture for 
human health risk assessment. These studies were all conducted in occupational settings, in which 
potential exposure concentrations may be high enough for interactions to occur. Some examples are 
presented below.  
Occupational  health  and  safety  professionals  use  a  “unity  calculation”  to  evaluate  whether  
over-exposure  occurs  when  workers  are  exposed  to  mixtures  of  chemicals  that  share  a  common 
mechanism of toxicity [52]. The unity calculation first converts the exposure concentration of each 
chemical in the mixture to a fraction of the corresponding reference occupational exposure limit (OEL) 
(i.e., exposure concentration divided by the  OEL). If the sum of these fractions (denoted as EM) 
exceeds unity (1.0), then the exposures should be reduced. This method assumes dose additivity, and it 
does not take into account PK or PD interactions. In a study conducted by Dennison and colleagues, 
the effect of PK interactions was factored in by using a human PBPK model for a mixture of toluene, 
ethylbeneze,  and  xylene  to  predict  venous  blood  concentrations  for  a  variety  of  exposure 
concentrations, as well as for different activity levels [53]. The predicted blood concentrations, instead 
of inhaled concentrations, were then used to derive an „internal dose-based EM‟, which is the sum of 
each chemical‟s blood concentration at the exposure concentration divided by that chemical‟s blood 
concentration at the OEL. They found that the traditional unity calculation that omits PK interactions Int. J. Environ. Res. Public Health 2011, 8                 
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can lead to significant over-exposures [53]. For example, in an exposure scenario based on exposure to 
one-third of the permissible exposure limit (PEL) for each chemical, the traditional unity calculation 
would  result  in  an  EM  of  1.0  (=  1/3  +  1/3  +  1/3).  However,  the  EM  calculated  based  on  blood 
concentrations was 2.9, suggesting that the cumulative blood concentrations of the three chemicals 
would be three times the concentration allowed by the PELs [XX]. Dennison and colleagues also 
found that workers with higher activity levels may experience significantly higher absorbed doses [53]. 
In another study, Jang and colleagues used PBPK modeling to investigate the interaction effects of a 
binary exposure to ethylbenzene and xylene for male workers who had been exposed to this mixture 
during  painting  and  solvent  mixing  [54].  The  PBPK  model-predicted  urinary  excretion  of 
methylhippuric acid (a metabolite of xylene) were 4.94 and 1.55 g/g creatinine when workers were 
exposed to 100 ppm of pure xylene and a mixture of 100 ppm of xylene and 25 ppm of ethylbenzene, 
respectively. The predicted result was consistent with that (1.96 g/g creatinine) calculated using the 
linear regression equation obtained from measured xylene and ethylbenzene concentrations in air and 
measured methylhippuric acid in urine [54]. Jang and colleagues concluded that PK interactions due to 
mixture exposures can significantly complicate the interpretation of biomonitoring data, and thus, PK 
interactions  should  be  considered  when  developing  biological  limit  values  (BLVs)  for  mixture 
exposures [54].  
As reviewed in Section 3.1.1, Dobrev and colleagues used a rat PBPK model to investigate the 
reduction of TCE metabolism caused by co-exposure to PERC and MC [14]. Dobrev and colleagues later 
scaled up the rat model to a human model for evaluating the impact of metabolic interactions in humans 
and its implications for risk assessment [55]. They found that inhibition of TCE metabolism in the 
presence of PERC and MC resulted in decreased formation of oxidative metabolites, but increased the 
formation  of  conjugative  metabolites,  S-1,2-dichlorovinylcysteine  (S-1,2-DCVC)  and  S-2,2-DCVC. 
Both  oxidative  and  conjugative  metabolites  of  TCE  have  been  associated  with  adverse  effects  in 
animals [56]. This study clearly demonstrated that human health risk associated with exposures to 
chemical mixtures is complexly related to the mechanism of interactions and the identity of the toxic 
moiety (e.g., parent or metabolite) [55].  
A similar conclusion was reached in a study that used a PBPK model for DBTEX to conduct both 
non-cancer and cancer risk assessments [57]. In this study, Haddad and colleagues scaled up a rat 
DBTEX model (reviewed in Section 3.1.2; [24]) to a human model to account for the effects of PK 
interactions on tissue dose metrics [57]. For the non-cancer risk assessment, the PBPK model predicted 
AUC  of  D,  B,  T,  E,  and  X  in  the  richly  perfused  tissue  compartment  (representing  brain)  were  
used as dose metrics for CNS effects; and the PBPK model predicted AUC of carboxyhemoglobin in 
blood was used as a dose metric for hypoxia [57]. These dose metrics were used to calculate an 
„interaction-based‟ hazard index (HI) for comparison with the conventional HI based on dose addition. 
Haddad and colleagues showed that, at high exposure concentrations, the interaction-based estimates 
of HI were higher for CNS effects, but lower for hypoxia [57]. For cancer risk assessment, Haddad and 
colleagues used the PBPK model-predicted amount of GSH conjugates as the dose surrogate for D and 
predicted the  amount  metabolized as  the dose surrogate  for  B.  Their analyses showed that in the 
presence  of  competitive  inhibitors  of  P450  metabolism  (B/D,  T,  E,  X),  cancer  risk  attributed  to  
D exposure increased; but cancer risk attributed to B exposure decreased [57].  Int. J. Environ. Res. Public Health 2011, 8                 
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Human PBPK models presented in the above examples were all scaled up from existing animal 
models. Human PBPK models can also be developed using in vitro data. For example, Haddad and 
colleagues developed a “physiologically based” liver model based on in vitro data to describe the 
inhibition, metabolism, transport, and partitioning of R-bufuralol, bunitrolol, and debrisoquine in the 
liver [XX]. The model was used to simulate the perfusate kinetics of each drug in an isolated perfused 
rat liver for the single and paired drugs. In Comparison with empirical models, the physiologically 
based liver model, overall, performed the best [58]. Although this work was on drug-drug interactions, 
the  approach  for  the  development  and  subsequent  application  of  a  PBPK  model  for  investigating 
chemical interactions is also applicable to environmental chemicals. The use of PBPK modeling in 
predicting drug-drug interactions can be found elsewhere (e.g., [59-61]). 
The  above  examples  represent  experience  with  applying  human  PBPK  models  for  chemical 
mixtures  in  cumulative  risk  assessment  for  predicting conditions  under  which  PK interactions are 
likely to alter the assumption of dose additivity. Human PD models, however, are yet to be utilized 
with  PBPK  models  to  assess responses  associated  with  exposures  to  chemical  mixtures  that  have 
common modes of action (e.g., cholinesterase inhibited by chlorpyrifos and carbaryl [Section 4.1]). 
Furthermore, the emerging discipline systems biology may assist in understanding how mixtures of 
chemicals affect a common physiological endpoint (e.g., interference with endocrine) by either similar 
or diverse modes of action in the body [6]. Systems biology studies biological systems by globally 
monitoring  the  gene,  protein,  and  pathway  responses  to  perturbations,  integrating  these  data  and 
formulating  mathematical  models  to  describe  the  structure  of  the  system  and  its  response  
dynamics [62]. Since the mode of action is related to the perturbation of biological systems, systems 
biology can help ascertain modes of actions that involve different pathway targets within cells, tissues, 
or  organs  [6].  Using  PBPK/PD  models  of  these  perturbations  allows  us  to  expand  the  current 
cumulative risk assessment paradigm to focus on the biology of responses more than on the kinetics of 
the chemicals [6].  
6. Conclusions 
Environmental exposure to multiple chemicals simultaneously or sequentially is the rule rather than 
an exception. When conducting cumulative risk assessment for chemicals in a mixture, the PK and PD 
interactions among chemicals need to be characterized since these interactions may cause alterations in 
the toxicity predicted based on the summation of the effects of each chemical. PK interactions occur 
when  one  chemical  alters  the  absorption,  distribution,  metabolism,  and/or  excretion  of  other 
chemical(s). PD interactions occur when one chemical alters the tissue response of other chemical(s). 
The  knowledge  on  PK  and/or  PD  interactions  can  be  integrated  in  a  quantitative  manner  with  a 
PBPK/PD model. A PBPK model can be used for dose, route and interspecies extrapolations of the 
target tissue concentration of the toxic moieties. A PD model can be used for describing mechanisms 
of action and tissue responses. An integrated PBPK/PD model for studying chemical interactions at 
both the level of PK (e.g., metabolic interactions) and PD (e.g., receptor interactions) is imperative to 
achieve the ultimate goal of assessing the health risks associated with human exposure to complex 
chemical mixtures. More than a science of observation, toxicology should be a science of observation 
and analysis. Int. J. Environ. Res. Public Health 2011, 8                 
 
1626 
Acknowledgements 
The authors would like to thank Jeffre Johnson and Marina Evans from the U.S. Environmental 
Protection Agency for their detailed review of the draft manuscript.  
Disclaimer 
The  United  States  Environmental  Protection  Agency  through  its  Office  of  Research  and 
Development collaborated in the research described here. It has been subjected to Agency review and 
approved for publication. 
References and Notes 
1.  Stork, L.G.; Gennings, C.; Carchman, R.A.; Carter, W.H.; Pounds, J.; Muntaz, M. Testing for 
additivity at select mixture groups of interest based on statistical equivalence testing methods. 
Risk Anal. 2006, 26, 1601-1612. 
2.  ATSDR. Gudiance Manual for the Assessment of Joint Toxic Action of Chemical Mixtures; U.S. 
Department of Health and Human Services, Agency for Toxic Substances and Disease Registry: 
Atlanta, GA, USA, 2002. 
3.  Ragas, M.J.; Oldenkamp, R.; Preeker, N.L.; Wernicke, J.; Schlink, U. Cumulative risk assessment 
of chemical exposures in urban environments. Environ. Int. 2011, 37, 872-881. 
4.  Kortenkamp,  A.;  Faust,  M.  Combined  exposures  to  anti-androgenic  chemicals:  Steps  towards 
cumulative risk assessment. Int. J. Androl. 2010, 33, 463-474. 
5.  Luciene da Silva, M.; Charest-Tardif, G.; Krishnan, K.; Tardif, R. Influence of oral administration 
of a quaternary mixture of triahlomethanes on their blood kinetics in the rat. Toxicol. Lett. 1999, 
106, 49-57. 
6.  Andersen, M.E.; Dennison, J.E. Mechanistic approaches for mixture risk assessments—present 
capabilities and future directions. Environ. Toxicol. Pharmacol. 2004, 16, 1-11. 
7.  Krishnan, K.; Brodeur, J. Toxicological consequences of combined exposure to environmental 
pollutants. Arch. Complex Environ. Stud. 1991, 3, 1-106. 
8.  Dennison, J.E.; Bigelow, P.L.; Andersen, M.E. Occupational exposure limits in the context of 
solvent mixtures, consumption of ethanol, and target tissue dose. Toxicol. Ind. Health 2004, 20, 
165-175. 
9.  Dekant, W. The role of biotransformation and bioactivation in toxicity. Experientia Suppl. 2009, 
99, 57-86.  
10.  Reddy, M.; Yang, R.S.H.; Clewell, H.J.; Andersen, M.E. Physiologically Based Pharmacokinetic 
Modeling: Science and Applications; John Wiley & Sons Inc.: Hoboken, NJ, USA, 2005. 
11.  Tardif,  R.;  Charest-Tardif,  G.  The  importance  of  measured  end-points  in  demonstrating  the 
occurrence of interactions: A case study with methylchloroform and m-xylene. Toxicol. Sci. 1999, 
49, 321-317. 
12.  Jollow,  D.J.;  Bruckner,  J.V.;  McMillan,  D.C.;  Fisher,  J.W.;  Hoel,  D.G.;  Mohr,  L.C. 
Trichloroethylene  risk  assessment:  A  review  and  commentary.  Crit.  Rev.  Toxicol.  2009,  39,  
782-797. Int. J. Environ. Res. Public Health 2011, 8                 
 
1627 
13.  Caldwell,  J.C.;  Keshava,  N.;  Evans,  M.V.  Difficulty  of  mode  of  action  determination  for 
trichloroethylene:  An  example  of  complex  interactions  of  metabolites  and  other  chemical 
exposures. Environ. Mol. Mutagen. 2008, 49, 142-154. 
14.  Dobrev, I.D.; Andersen, M.E.; Yang, R.S. Assessing interaction thresholds for trichloroethylene 
in combination with tetrachloroethylene and 1,1,1-trichloroethane using gas uptake studies and 
PBPK modeling. Arch. Toxicol. 2001, 75, 134-144. 
15.  De Rosa, C.T.; El-Masri, H.A.; Pohl, H.; Cibulas, W.; Mumtaz, M.M. Implications of chemical 
mixtures in public health practice. J. Toxicol. Environ. Health B Crit. Rev. 2004, 7, 339-350. 
16.  Dekant,  W.;  Martens,  G.;  Vamvakas,  S.;  Metzler,  M.;  Henschler,  D.  Bioactivation  of 
tetrachloroethylene. Role of glutathione S-transferase-catalyzed conjugation versus cytochrome  
P-450-dependent phospholipid alkylation. Drug Metabol. Dispos. 1987, 15, 702-709. 
17.  Bruckner, J.V.; Kyle, G.M.; Luthra, R.; Acosta, D.; Mehta, S.M.; Sethuraman, S.; Muralidhara, S. 
Acute, short-term and subchronic oral toxicity of 1,1,1-trichloroethane in rats. Toxicol. Sci. 2001, 
60, 363-372. 
18.  Andersen,  M.E.;  Gargas,  M.L.;  Clewell,  H.J.;  Severyn,  K.M.  Quantitative  evaluation  of  the 
metabolic interaction between trichloroethylene and 1,1-dichloroethylene in vivo using gas uptake 
methods. Toxicol. Appl. Pharmacol. 1987, 89, 149-157. 
19.  Jaeger,  R.J.;  Conolly,  R.B.;  Murphy,  S.D.  Effect  of  18  hr  fast  and  glutathione  depletion  on  
1,1-dichloroehtylene-induced  hepatotoxicity  and  lethality  in  rats.  Exp.  Mol.  Pathol.  1974,  20,  
187-198. 
20.  Watanabe,  P.G.;  Zempel,  J.A.;  Pegg,  D.G.;  Gehring,  P.J.  Hepatic  macromolecular  binding 
following exposure to vinyl chloride. Toxicol. Appl. Pharmacol. 1978, 77, 571-579. 
21.  Purcell,  K.J.;  Cason,  G.H.;  Gargas,  M.L;  Andersen,  M.E.;  Travis,  C.C.  In  vivo  metabolic 
interactions of benzene and toluene Toxicol. Lett. 1990, 52, 141-152. 
22.  Tardif, R.; Charest-Tardif, G.; Brodeur, J.; Krishnan, K. Physiologically based pharmacokinetic 
modeling of a ternary mixture of alkyl benzenes in rats and humans. Toxicol. Appl. Pharmacol. 
1997, 144, 120-134. 
23.  Haddad,  S.;  Charest-Tardif,  G.;  Tardif,  R.;  Krishnan,  K.  Physiological  modeling  of  the 
toxicokinetic  interactions  in  a  quaternary  mixture  of  aromatic  hydrocarbons.  Toxicol.  Appl. 
Pharmacol. 1999, 161, 249-257. 
24.  Haddad, S.; Charest-Tardif, G.; Tardif, R.; Krishnan, K. Validation of a physiological modeling 
framework for simulating the toxicokinetics of chemicals in mixtures. Toxicol. Appl. Pharmacol. 
2000, 167, 199-209. 
25.  Price,  K.;  Krishnan,  K.  An  integrated  QSAR-PBPK  modeling  approach  for  predicting  the 
inhalation toxicokinetics of mixtures of volatile organic chemicals in the rat. SAR QSAR Environ. 
Res. 2011, 22, 107-128. 
26.  Dennison,  J.E.;  Andersen,  M.E.;  Yang,  R.S.H.  Characterization  of  the  pharmacokinetics  of 
gasoline  using  PBPK  modeling  with  a  complex  mixtures  chemical  lumping  approach.  Inhal. 
Toxicol. 2003, 15, 964-986. 
27.  ATSDR. Toxicological Profile of Carbon Tetrachloride—Draft; U.S. Department of Health and 
Human Services, Agency for Toxic Substances and Disease Registry: Atlanta, GA, USA, 2003. Int. J. Environ. Res. Public Health 2011, 8                 
 
1628 
28.  Mehendale,  H.M.  Role  of  hepatocellular  regeneration  and  hepatolobular  healing  in  the  final 
outcome  of  liver  injury.  A  two-stage  model  of  toxicity.  Biochem.  Pharmacol.  1991,  42,  
1155-1162. 
29.  Evans,  M.V.;  Simmons,  J.E.  Physiologically  based  pharmacokinetic  estimated  metabolic 
constants and hepatotoxicity of carbon tetrachloride after methanol pretreatment in rats. Toxicol. 
Appl. Pharmacol. 1996, 140, 245-253. 
30.  Simmons,  J.E.;  McDonald,  A.;  Seely,  J.C.;  Sey,  Y.M.  Potentiation  of  carbon  tetrachloride 
hepatotoxicity by inhaled methanol: Time course of injury and recovery. J. Toxicol. Environ. 
Health 1995, 46, 203-216. 
31.  Thakore,  K.N.;  Gargas,  M.L.;  Andersen,  M.E.;  Mehendale,  H.M.  PB-PK  derived  metabolic 
constants,  hepatotoxicity,  and  lethality  of  BrCCl3  in  rats  pretreated  with  chlordecone, 
phenobarbital or mirex. Toxicol. Appl. Pharmacol. 1991, 109, 514-528. 
32.  El-Masri, H.; Mumtaz, M.; Yushak, M. Application of physiologically-based pharmacokinetic 
modeling to investigate the toxicological interaction between chlorpyrifos and parathion in the rat. 
Environ. Toxicol. Pharmacol. 2004, 16, 57-71. 
33.  ATSDR. Toxicological Profile of Chlorpyrifos; U.S. Department of Health and Human Services, 
Agency for Toxic Substances and Disease Registry: Atlanta, GA, USA, 1997. 
34.  Sultatos, L.G.; Minor, L.D.; Murphy, S.D. Metabolic activation of phosphorothioate pesticides: 
Role of the liver. J. Pharmacol. Exp. Ther. 1985, 232, 624-628. 
35.  Sams, C.; Mason, H.J.; Rawbone, R. Evidence for the activation of organophosphate pesticides by 
cytochromes P450 3A4 and 2D6 in human liver microsomes. Toxicol. Lett. 2000, 116, 217-221.  
36.  Huff, R.A.; Corcoran, J.J.; Anderson, J.K.; Abou-Donia, M.B. Chlorpyrifos oxon binds directly to 
muscarinic receptors and inhibits cAMP accumulation in rat striatum. J. Pharmacol. Exp. Ther. 
1994, 269, 329-335. 
37.  Costa,  L.G.;  McDonald,  B.E.;  Murphy,  S.D.;  Omenn,  G.S.;  Richter,  R.J.;  Motulsky,  A.G.; 
Furlong, C.E. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in 
rats. Toxicol. Appl. Pharmacol. 1990, 103, 66-76. 
38.  Mutch, E.; Daly, A.K.; Leathart, J.B; Blain, P.G.; Williams, F.M. Do multiple cytochrome P450 
isoforms contribute to parathion metabolism in man? Arch. Toxicol. 2003, 77, 313-320. 
39.  Timchalk,  C.;  Poet,  T.S.  Development  of  a  physiologically  based  pharmacokinetic  and 
pharmacodynamic  model  to  determine  dosimetry  and  cholinesterase  inhibition  for  a  binary 
mixture of chlorpyrifos and diazinon in the rat. Neurotoxicol. Teratol. 2008, 29, 428-443. 
40.  Timchalk,  C.;  Nolan,  R.J.;  Mendrala,  A.L.;  Dittenber,  D.A;  Brzak,  K.A.;  Mattsson,  J.L.  
A  physiologically  based  pharmacokinetic  and  pharmacodynamic  (PBPK/PD)  model  for  the 
organophosphate insecticide chlorpyrifos in rats and humans. Toxicol. Sci. 2002, 66, 34-53. 
41.  Nong, A.; Tan, Y.; Krolski, M.E.; Wang, J.; Lunchick, C.; Conolly, R.B.; Clewell, H.J. Bayesian 
calibration  of  a  physiologically  based  pharmacokinetic/pharmacodynamic  model  of  carbaryl 
cholinesterase inhibition. J. Toxicol. Environ. Health 2008, 71, 1363-1381. 
42.  Campbell,  J.L.;  Krishnan,  K.;  Clewell,  H.J.;  Andersen, M.E.  Kinetic  interactions  of  chemical 
mixtures. In Principles and Practice of Mixtures Toxicology; Mumtaz, M., Ed.; Wiley: Weinheim, 
Germany, 2010. Int. J. Environ. Res. Public Health 2011, 8                 
 
1629 
43.  Mehendale,  H.M.  Amplified  interactive  toxicity  of  chemicals  at  nontoxic  levels:  Mechanistic 
considerations and implications to public health. Environ. Health Perscept. 1994, 102 (Suppl 9), 
139-149. 
44.  Curtis,  L.R.;  Williams,  W.L.;  Mehendale,  H.M.  Potentiation  of  the  hepatotoxicity  of  carbon 
tetrachloride  following  preexposure  to  chlordecone  (kepone)  in  the  male  rat.  Toxicol.  Appl. 
Pharmacol. 1979, 51, 283-293. 
45.  Agarwal, A.K.; Mehendale, H.M. Potentiation of CCl4 hepatotoxicity and lethality by chlordecone 
in female rats. Toxicology 1983, 26, 231-242. 
46.  Lockard,  V.G.;  Mehendale,  H.M.;  O‟Neal,  R.M.  Chlordecone-induced  potentiation  of  carbon 
tetrachloride heaptotoxicity: A light and electron microscopic study. Exp. Mol. Pathol. 1983, 39, 
230-245. 
47.  Lockard,  V.G.;  Mehendale,  H.M.;  O‟Neal,  R.M.  Chlordecone-induced  potentiation  of  carbon 
tetrachloride heaptotoxicity: A morphometric and biochemical study. Exp. Mol. Pathol. 1983, 39, 
246-255. 
48.  Mehendale, H.M. Mechanism of the lethal interaction of chlordecone and CCl4 at non-toxic doses. 
Toxicol. Lett. 1989, 49, 215-241. 
49.  Kodavanti,  P.R.;  Kodavanti,  U.P.;  Faroon,  O.M.;  Mehendale,  H.M.  Pivotal  role  of  
hepatocellular  regeneration  in  the ultimate  hepatotoxicity  of  CCl4  in  chlordecone-,  mirex-,  or 
Phenobarbital-pretreated rats. Toxicol. Pathol. 1992, 20, 556-569. 
50.  Cai, Z.; Mehendale, H.M. Resiliency to amplification of carbon tetrachloride hepatotoxicity by 
chlordecone during postnatal development in rats. Pediatr. Res. 1993, 33, 225-232. 
51.  El-Masri,  H.A.;  Thomas,  R.S.;  Sabados,  G.R.;  Phillips,  J.K.;  Constan,  A.A.;  
Benjamin,  S.A.;  Andersen,  M.E.;  Mehendale,  H.M.;  Yang,  R.S.  Physiologically  based 
pharmacokinetic/pharmacodynamic  modeling  of  the  toxicologic  interaction  between  carbon 
tetrachloride and kepone. Arch. Toxicol. 1996, 70, 704-713. 
52.  29  CFR  1910.1000—Air  Contaminants.  Code  of  Federal  Regulations—Title  29:  Labor; 
Occupational Safety and Health Administration (OSHA): Washington, DC, USA, 2004. 
53.  Dennison,  J.E.;  Bigelow,  P.L.;  Mumtaz,  M.M.;  Andersen,  M.E.;  Dobrev,  I.D.;  Yang,  R.S.H. 
Evaluation of potential toxicity from co-exposure to three CNS depressants (toluene, ethylbenzene, 
and xylene) under resting and working conditions using PBPK modeling. J. Occup. Environ. Hyg. 
2005, 2, 127-135. 
54.  Jang, J.Y.; Droz, P.O.; Kim, S. Biological monitoring of workers exposed to ethylbenzene and  
co-exposed to xylene. Int. Arch. Occup. Environ. Health 2001, 74, 31-37. 
55.  Dobrev,  I.D.;  Andersen,  M.E.;  Yang,  R.S.H.  In  silico  toxicology:  Simulating  interaction 
thresholds  for  human  exposure  to  mixtures  of  trichloroethylene,  tetrachloroethylene,  and  
1,1,1-trichloroethane. Environ. Health Perspect. 2002, 110, 1031-1039. 
56.  Lash, L.H.; Fisher, J.W.; Lipscomb, J.C.; Parker, J.C. Metabolism of trichloroethylene. Environ. 
Health Perspect. 2000, 108, 177-200. 
57.  Haddad, S.; Bé liveau, M.; Tardif, R.; Krishnan, K. A PBPK modeling-based approach to account 
for  interactions  in  the  health  risk  assessment  of  chemical  mixtures.  Toxicol.  Sci.  2001,  63,  
125-131. Int. J. Environ. Res. Public Health 2011, 8                 
 
1630 
58.  Haddad, S.; Poulin, P.; Funk, C. Extrapolating in vitro metabolic interactions to isolated perfused 
liver: Predictions of metabolic interactions between R-Bufuralol, Bunitrolol, and Debrisoquine.  
J. Pharm. Sci. 2010, 99, 4406-4426.  
59.  Vossen,  M.;  Sevestre,  M.;  Niederalt,  C.;  Jang,  I.;  Willmann,  S.;  Edginton,  A.  Dynamically 
simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual 
coupled  whole-body  physiologically-based  pharmacokinetic  (WB-PBPK)  models.  Theor.  Biol. 
Med. Model. 2007, 4, 13. 
60.  Kato,  M.;  Shitara,  Y.;  Sato,  H.;  Yoshisue,  K.;  Hirano,  M.;  Ikeda,  T.;  Sugiyama,  Y.  
The  quantitative  prediction  of  CYP-mediated  drug  interaction  by  physiologically  based 
pharmacokinetic modeling. Pharmacol. Res. 2008, 25, 1891-1901. 
61.  Rowland, M.; Peck, C.; Tucker, G. Physiologically-based pharmacokinetics in drug development 
and regulatory science. Annu. Rev. Pharmacol. Toxicol. 2011, 51, 45-73. 
62.  Ideker, T.; Galitski, T.; Hood, L. A new approach to decoding life: Systems biology. Annu. Rev. 
Genom. Hum. Genet. 2001, 2, 343-372. 
©  2011  by  the  authors;  licensee  MDPI,  Basel,  Switzerland.  This  article  is  an  open  access  article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 